Generation of lentivirus vectors using recombinant baculoviruses

Gene Therapy

Volumn 15, Issue 18, 2008, Pages 1280-1286

  Lesch, H P ^a,b   Turpeinen, S ^a,b   Niskanen, E A ^c   Mahonen A J ^a,b   Airenne, K J ^a   Yla Herttuala S ^a,d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Finland Ark Therapeutics Oy   (Finland)

^c UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; THROMBOSPONDIN; VIRUS GLYCOPROTEIN;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BACULOVIRUS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MAMMAL CELL; MOLECULAR CLONING; NONHUMAN; PLASMID; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CHARACTERIZATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TITRATION;

BACULOVIRIDAE; CELL LINE; CLONING, MOLECULAR; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; LENTIVIRUS; MICROSCOPY, FLUORESCENCE; ORGANISMS, GENETICALLY MODIFIED; TRANSDUCTION, GENETIC; TRANSGENES; VIROLOGY; VIRUS REPLICATION;

LENTIVIRUS; MAMMALIA; VESICULAR STOMATITIS VIRUS;

EID: 51249098122     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.76     Document Type: Article

References (46)

1. Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves > 99% transduction in primary cells using a one-step protocol. J Gene Med 2004; 6: 963-973.
2. Follenzi A, Naldini L. Generation of FEV-1 derive lentiviral vectors. Methods Enzymol 2002; 346: 454-465.
3. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006; 1: 241-245.
4. Geraerts M, Miels M, Baekelandt V, Debyser Z, Gijsbers R. Upscahng of lentiviral vector production by tangential flow filtration. J Gene Med 2005; 7: 1299-1310.
5. Segura MM, Garnier A, Durocher Y, Coelho H, Kamen A. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol Bioeng 2007; 98: 789-799.
6. Kafri T, van PH, Ouyang L, Gage FH, Verma IM. A packaging cell line for lentivirus vectors. J Virol 1999; 73: 576-584.
7. Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 2001; 12: 981-997.
8. Pacchia AL, Adelson ME, Kaul M, Ron Y, Dougherty JP. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of FHV-1 accessory proteins. Virology 2001; 282 77-86.
9. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 2001; 3: 97-104.
10. Haselhorst D, Kaye JF, Lever AM. Development of cell lines stably expressing human immunodeficiency virus type 1 proteins for studies in encapsidation and gene transfer. J Gen Virol 1998; 79 (Part 2): 231-237.
11. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005; 5: 387-398.
12. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033-8037.
13. Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J Gene Med 2005; 7 819-834.
14. Strang BL, Ikeda Y, Cosset FL, Collins MK, Takeuchi Y. Characterization of HIV-1 vectors with gammaretrovirug envelope glycoproteins produced from stable packaging cells. Gene Therapy 2004; 11: 591-598.
15. Strang BL, Takeuchi Y, Relander T, Richter J, Bailey R, Sanders DA et al. Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells. J Virol 2005; 79: 1765-1771.
16. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW. Optimized large-scale production of high titer lentivinis vector pseudotypes. J Virol Methods 2004; 122: 131-139.
17. Kumar M, Bradow BP, Zimmerberg J. Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64. Hum Gene Ther 2003; 14: 67-77.
18. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. A Rev-independent human immunodeficiency virus type 1 (HrV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74: 4839-4852.
19. Koldej R, Cmielewski P, Stocker A, Parsons DW, Anson DS. Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production. J Gene Med 2005; 7: 1390-1399.
20. Wu X, Wakefield JK, Liu H, Xiao H, Kralovics R, Prchal JT et al. Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2000; 2: 47-55.
21. O'reilly DR, Miller LK, Luckov VA. Baculovirus Expression Vectors. A laboratory Manual. Oxford University Press: New York, 2004.
22. Airenne KJ, Mahonen AJ, Laitinen OH, Yla-Herttuala S. Baculovirus-mediated gene transfer: An evolving new concept. In: Templeton NS (ed). Gene and Cell Therapy. Marcel Dekker Inc.: New York, NY, 2004, pp 181-197.
23. Poomputsa K, Kittel C, Egorov A, Ernst W, Grabherr R. Generation of recombinant influenza virus using baculovirus delivery vector. J Virol Methods 2003; 110: 111-114.
24. Cheshenko N, Krougliak N, Eisensmith RE, Krougliak VA. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gene Therapy 2001; 8: 846-854.
25. Sollerbrant K, Elmen J, Wahlestedt C, Acker J, Leblois-Prehaud H, Latta-Mahieu M et al. A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. J Gen Virol 2001; 82: 2051-2060.
26. Huang KS, Lo WH, Chung YC, Lai YK, Chen CY, Chou ST et al. Combination of baculovirus-mediated gene delivery and packed-bed reactor for scalable production of adeno-associated virus. Hum Gene Ther 2007; 18: 1161-1170.
27. Chen YH, Wu JC, Wang KC, Chiang YW, Lai CW, Chung YC et al. Baculovirus-mediated production of HDV-hke particles in BHK cells using a novel oscillating bioreactor. J Biotechnol 2005; 118: 135-147.
28. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
29. Sastry L, Xu Y, Johnson T, Desai K, Rissing D, Marsh J et al. Certification assays for HIV-1-based vectors: Frequent passage of gag sequences without evidence of replication-competent viruses. Mol Ther 2003; 8: 830-839.
30. Scott MJ, Modha SS, Rhodes AD, Broadway NM, Hardwicke PL, Zhao HJ et al. Efficient expression of secreted proteases via recombinant BacMam. virus. Protein Expr Purif 2007; 52: 104-116.
31. Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA 1995; 92: 10099-10103.
32. Burges HD, Croizier G, Huger J. A review of safety tests on baculoviruses. Entomophaga 1980; 25: 329-340.
33. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13 1935-1943.
34. Mahonen AJ, Airenne KJ, Purola S, Peltomaa E, Kaikkonen MU, Riekkinen MS et al. Post-transcriptional regulatory element boosts baculovirus-mediated gene expression in vertebrate cells. J Biotechnol 2007; 131: 1-8.
35. Hsu CS, Ho YC, Wang KC, Hu YC. Investigation of optimal transduction conditions for baculovirus-mediated gene delivery into mammalian cells. Biotechnol Bioeng 2004; 88: 42-51.
36. Rodrigues T, Carrondo MJ, Alves PM, Cruz PE. Purification of retroviral vectors for clinical application: Biological implications and technological challenges. J Biotechnol 2007; 127; 520-541.
37. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
38. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-8157.
39. Sinn PL, Sauter SL, McCray Jr PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors- design, biosafety, and production. Gene Therapy 2005; 12:1089-1098.
40. Gheysen D, Jacobs E, de FF, Thiriart C, Francotte M, Thines D et al Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1999; 59: 103-112.
41. Nermut MV, Hockley DJ, Jowett JB, Jones IM, Garreau M, Thomas D. Fullerene-like organization of HIV gag-protein shell in virus-like particles produced by recombinant baculovirus. Virology 1994; 198: 288-296.
42. Jones IM, Morikawa Y. The molecular basis of HIV capsid assembly. Rev Med Virol 1998; 8: 87-95.
43. Makinen PI, Koponen JK, Karkkainen AM, Mahn TM, Pulkkinen KH, Koistirtaho J et al. Stable RNA interference: Comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med 2006; 8: 433-441.
44. Airenne KJm Hiltunen MO, Turunen MP, Turunen AM, Laitinen OH, Kulomaa MS et al. Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery. Gene Therapy 2000; 7: 1499-1504.
45. Airenne KJ, Peltomaa E, Hytonen VP, Laitinen OH, Yla-Herttuala S. improved generation of recombinant baculovirus genomes in Escherichia coli. Nucleic Acids Res 2003; 31: E101l.
46. Cha HJ, Gotoh T, Bentley WE. Simplification of titer determination for recombinant baculovirus by green fluorescent protein marker. Biotechniques 1997; 23: 782, 784, 786.